Polypeptide and pharmaceutical composition containing the polypeptide

A composition and drug technology, applied in the field of pharmaceutical compositions containing the polypeptide, can solve the problems of angiogenesis and symptom deterioration, and achieve the effects of reducing manufacturing costs and excellent stability
CN101977931AInactive Publication Date: 2011-02-16HOKKAIDO UNIVERSITY +1
3 Cites 4 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
HOKKAIDO UNIVERSITY
Publication Date
2011-02-16
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

Disclosed is a novel polypeptide which can inhibit angiogenesis. Also disclosed is use of the polypeptide. The polypeptide comprises at least one amino acid sequence selected from the amino acid sequences depicted in SEQ ID NOs: 1-3, is composed of 120 or less amino acid residues, and has an anti-angiogenic activity. The polypeptide has an anti-angiogenic activity, has a lower molecular weight compared with that of PEDF, and has excellent penetration or absorption into a living body, particularly an affected part in a living body.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to a polypeptide capable of effectively treating or preventing diseases involving angiogenesis, an anti-angiogenesis agent containing the polypeptide as an active ingredient, or a pharmaceutical composition containing the polypeptide. Background technique

[0002] In humans, angiogenesis is induced only at the right time or place under the tight control of a functional balance between angiogenic-promoting and anti-angiogenic factors, eg, during wound healing and specific phases of the menstrual cycle.

[0003] However, it is known that, in certain diseases, the above-mentioned regulation fails for some reason, leading to undesired angiogenesis and exacerbation of symptoms. For example, in diabetic retinopathy and age-related macular degeneration, neovascularization in the iris, retina or optic nerve has been observed, and this is known to cause severe vision loss. Furthermore, angiogenesis is also known to be induced in s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More